Literature DB >> 23435803

IgM monoclonal gammopathy in gastric MALToma.

Zhineng J Yang1, Gurprataap S Sandhu, Nidhi Aggarwal, Kenneth E Fasanella, Mounzer Agha.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 23435803     DOI： 10.1007/s12029-013-9483-9

Source DB:  PubMed          Journal:  J Gastrointest Cancer


× No keyword cloud information.
  28 in total

1.  Low-grade MALT lymphoma mimicking Waldenström's macroglobulinemia.

Authors:  M Allez; X Mariette; G Linares; P Bertheau; R Jian; J C Brouet
Journal:  Leukemia       Date:  1999-03       Impact factor: 11.528

2.  Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone.

Authors:  N R Schechter; C S Portlock; J Yahalom
Journal:  J Clin Oncol       Date:  1998-05       Impact factor: 44.544

3.  Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication.

Authors:  Thomas Wündisch; Christian Thiede; Andrea Morgner; Astrid Dempfle; Annette Günther; Hongxiang Liu; Hongtao Ye; Ming-Qing Du; Theo D Kim; Ekkehard Bayerdörffer; Manfred Stolte; Andreas Neubauer
Journal:  J Clin Oncol       Date:  2005-10-03       Impact factor: 44.544

4.  Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG).

Authors:  A Conconi; G Martinelli; A Lopez-Guillermo; P L Zinzani; A J M Ferreri; L Rigacci; L Devizzi; U Vitolo; S Luminari; F Cavalli; E Zucca
Journal:  Ann Oncol       Date:  2010-09-01       Impact factor: 32.976

5.  Treatment outcome of mucosa-associated lymphoid tissue/marginal zone non-Hodgkin's lymphoma.

Authors:  Stacie Hitchcock; Andrea K Ng; David C Fisher; Barbara Silver; M Patricia Bernardo; David M Dorfman; Peter M Mauch
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-03-15       Impact factor: 7.038

6.  Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan.

Authors:  Shotaro Nakamura; Toshiro Sugiyama; Takayuki Matsumoto; Katsunori Iijima; Shouko Ono; Masahiro Tajika; Akira Tari; Yasuhiko Kitadai; Hiroshi Matsumoto; Tadanobu Nagaya; Toshiro Kamoshida; Norihiko Watanabe; Toshimi Chiba; Hideki Origasa; Masahiro Asaka
Journal:  Gut       Date:  2011-09-02       Impact factor: 23.059

7.  18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma.

Authors:  Lapo Alinari; Paolo Castellucci; Rebecca Elstrom; Valentina Ambrosini; Vittorio Stefoni; Cristina Nanni; Arnold Berkowitz; Monica Tani; Mohsen Farsad; Roberto Franchi; Stefano Fanti; Pier Luigi Zinzani
Journal:  Leuk Lymphoma       Date:  2006-10

8.  A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas.

Authors:  Jennifer R Brown; Jonathan W Friedberg; Yang Feng; Sarah Scofield; Kimberly Phillips; Paola Dal Cin; Robin Joyce; Ronald W Takvorian; David C Fisher; Richard I Fisher; Jane Liesveld; Diana Marquis; Donna Neuberg; Arnold S Freedman
Journal:  Br J Haematol       Date:  2009-03-30       Impact factor: 6.998

9.  Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type.

Authors:  Antonio Salar; Eva Domingo-Domenech; Cristina Estany; Miguel A Canales; Fernando Gallardo; Octavio Servitje; Guadalupe Fraile; Carlos Montalbán
Journal:  Cancer       Date:  2009-11-15       Impact factor: 6.860

Review 10.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.

Authors:  N L Harris; E S Jaffe; H Stein; P M Banks; J K Chan; M L Cleary; G Delsol; C De Wolf-Peeters; B Falini; K C Gatter
Journal:  Blood       Date:  1994-09-01       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.